{"id":25437,"date":"2022-06-23T14:53:29","date_gmt":"2022-06-23T13:53:29","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=25437"},"modified":"2022-06-23T14:53:32","modified_gmt":"2022-06-23T13:53:32","slug":"2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/","title":{"rendered":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis"},"content":{"rendered":"\n<p>Article published on May 27, 2022 on the <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240047655\" target=\"_blank\" rel=\"noreferrer noopener\">World Health Organization website<\/a><\/p>\n\n\n\n<p>The World Health Organization\u2019s (WHO) \u201c2021 Antibacterial agents in clinical development and preclinical: an overview and analysis\u201d<strong>&nbsp;<\/strong>report evaluates the pipelines of antibacterial candidates in different stages of development.<\/p>\n\n\n\n<p>This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent the present pipeline addresses infections caused by&nbsp;<a href=\"https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed\" target=\"_blank\" rel=\"noreferrer noopener\">WHO Priority Pathogens<\/a>,&nbsp;<em>Mycobacterium tuberculosis&nbsp;<\/em>and&nbsp;<em>Clostridioides difficile.<\/em>&nbsp;The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and\/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.<\/p>\n\n\n\n<p>This report is part of the WHO\u2019s efforts to prioritize and coordinate global research and development (R&amp;D) efforts to address the discovery void in antibacterial drug development.<\/p>\n\n\n\n<p><strong>All of the data contained in this report can be downloaded from the WHO Global Observatory on Health R&amp;D:<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/antibacterial-products-in-clinical-development-for-priority-pathogens\" target=\"_blank\" rel=\"noreferrer noopener\">Data for the clinical pipeline<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/who-antibacterial-preclinical-pipeline-review\" target=\"_blank\" rel=\"noreferrer noopener\">Data for the preclinical pipeline<\/a><\/p>\n\n\n\n<p><strong>WHO R&amp;D and pipeline infographics:<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/cdn.who.int\/media\/docs\/default-source\/antimicrobial-resistance\/amr-gcp-irc\/2020-antibacterial-agents-in-clinical-and-preclinical-development.pdf?sfvrsn=2c480edd_5\" target=\"_blank\" rel=\"noreferrer noopener\">2020 Antibacterial agents in clinical and preclinical development<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/cdn.who.int\/media\/docs\/default-source\/antimicrobial-resistance\/amr-gcp-irc\/five-key-points-to-consider-for-the-development-and-optimal-use-of-new-antibiotics.pdf?sfvrsn=c4a77671_5\" target=\"_blank\" rel=\"noreferrer noopener\">Five key points to consider for the development and optimal use of new antibiotics<\/a><\/p>\n\n\n\n<p>Download global report <a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240047655\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on May 27, 2022 on the World Health Organization website The World Health Organization\u2019s (WHO) \u201c2021 Antibacterial agents in clinical development and preclinical: an overview and analysis\u201d&nbsp;report evaluates the pipelines of antibacterial candidates in different stages of development. This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":25445,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-23T13:53:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T13:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"919\" \/>\n\t<meta property=\"og:image:height\" content=\"613\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis\",\"datePublished\":\"2022-06-23T13:53:29+00:00\",\"dateModified\":\"2022-06-23T13:53:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\",\"name\":\"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg\",\"datePublished\":\"2022-06-23T13:53:29+00:00\",\"dateModified\":\"2022-06-23T13:53:32+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg\",\"width\":919,\"height\":613,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Reviews, reports and recommendations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/","og_locale":"en_GB","og_type":"article","og_title":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-06-23T13:53:29+00:00","article_modified_time":"2022-06-23T13:53:32+00:00","og_image":[{"width":919,"height":613,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis","datePublished":"2022-06-23T13:53:29+00:00","dateModified":"2022-06-23T13:53:32+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/"},"wordCount":254,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/","name":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg","datePublished":"2022-06-23T13:53:29+00:00","dateModified":"2022-06-23T13:53:32+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/06\/Science-labo-recherche.jpg","width":919,"height":613,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antibacterial-agents-in-clinical-and-preclinical-development-a-world-health-organization-overview-and-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Reviews, reports and recommendations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/reviews-reports-recommendations\/"},{"@type":"ListItem","position":4,"name":"2021 Antibacterial agents in clinical and preclinical development: a World Health Organization overview and analysis"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-12 16:38:51","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/25437"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=25437"}],"version-history":[{"count":6,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/25437\/revisions"}],"predecessor-version":[{"id":25453,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/25437\/revisions\/25453"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/25445"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=25437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=25437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=25437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}